Sanofi-Aventis, the French company that is developing the promising obesity drug Acomplia (rimonabant), has disclosed that it soon intends to initiate studies aimed at determining whether Acomplia (rimonabant) can be used to treat and prevent clogged arteries and heart disease.
Dr. Douglas Greene, Sanofi-Aventis vice president for corporate and regulatory affairs, said the idea of using Acomplia in this way stemmed from the discovery that even patients people who did not lose weight in the obesity trials currently underway saw an increase in their Acomplia (rimonabant) HDL (good) cholesterol and a lowering of their triglycerides.
At a meeting of the North American Association for the Study of Obesity, Greene said Sanofi plans to conduct two studies of the drug in obese smokers with blood--fat abnormalities to see whether Acomplia can slow or prevent the buildup of blockages Acomplia (rimonabant) .
One trial will enroll people getting an angiogram to open a clogged artery. Researchers will choose a smaller artery that is not being treated and measure changes in the amount of blockage over time on the Acomplia (rimonabant) drug.
Greene also said that when Sanofi files for U.S. Food and Drug Administration approval to market Acomplia for fighting obesity and helping smokers kick the habit, the company also may seek labeling saying the drug can be used to prevent metabolic syndrome Acomplia (rimonabant) .
Acomplia (rimonabant) Metabolic syndrome is characterized by a group of risk factors that include excessive fat in and around the abdomen, high triglycerides, low HDL cholesterol, and insulin resistance or glucose intolerance — all factors that have seemed in the trials to improve for patients taking Acomplia.
Метки:
drug,
fat,
lose weight,
obese,
obesity,
obesity drug,
study,
Zimulti
Посмотрите также
- New Acomplia Study Has More Good News for Obese Diabetics
The latest results of the last of four major Acomplia (rimonabant) studies added more good news to the mounting excitement about this breakthrough obesity drug.
Not only does Acomplia help obese people Acomplia (rimonabant) lose weight, raise their good cholesterol, lower their triglicerides, and reduce other cardiac risk [...]
- Expert Says Overactive Endocannabinoid System May Be Key Factor in Obesity
Dr. Louis J. Aronne, a leading authority on obesity and long a strong supporter of diet drug rimonabant (Acomplia / Zimulti) , says “what many people have traditionally viewed as a lack of willpower [to stop eating] could actually have a biochemical basis” found in the endocannabinoid (EC) system.
“ [...]
- Causes of Obesity-Environmental Factors
Causes of Obesity-Environmental Factors
Along with genetics, environmental factors have been found to contribute to obesity. In particular, increased food consumptionand an inactive (sedentary) lifestyle are environmental factors that very closely correlate with an increased risk of obesity.Americans have an ever-increasing number of energydense foods, packaged in enormous portions, conveniently available at low cost.
Energy-dense foods contain [...]
- 600 European Patients to Be Enrolled in New Trial of Obesity Drug ATL-962
A second Phase IIb clinical trial has been approved by British regulators to evaluate ATL-962 for the treatment of obesity in up to 600 clinically obese diabetic patients.
The randomised, double-blind trial Acomplia (rimonabant) will compare three doses of ATL-962 with a placebo and with the obesity drug Xenical.
[...]
- Zimulti Acomplia News About Rimonabant Sales of Acomplia Lag, But Sanofi Still Has High Hopes for Rimonabant
With sales of Acomplia (rimonabant) lagging in the several dozen countries where it is on the market, Sanofi-Aventis executives had little to say about their pioneering obesity treatment in a report to analysts on Feb. 12th. But that hardly means they have given up on the CB-1 receptor antagonist. [...]
- Study: Acomplia Produces Weight Loss and Metabolic Improvement
Quebec City, Canada, March 9, 2004 - Results of a Phase III clinical trial (RIO-Lipids or Rimonabant In Obesity) comparing rimonabant, the first drug in a new Acomplia (rimonabant) class called Selective CB1 Blockers (or SCB1Bs), to placebo found that overweight or obese patients with untreated dyslipidemia (high triglycerides, low HDL-cholesterol) lost [...]
If you enjoyed this post, please consider to leave a comment or subscribe to the feed and get future articles delivered to your feed reader.
Comments
Еще нет комментариев.
Извините, комментирование на данный момент закрыто.